FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
86 -
The diagnostic utility of miRNA21 in systemic sclerosis
698PDF: 54SUPPLEMENTARY MATERIAL: 15 -
PO:06:079 | Weighing the burden: how body mass index shapes clinical outcomes in rheumatoid arthritis. Insights from a large Italian cohort Marco Capodiferro1, Marco Fornaro1, Gian Luca Erre2, Matteo Piga3, Elena Bartoloni Bocci4, Andreina Manfredi5, Ennio Giulio Favalli6, Maria Sole Chimenti7, Serena Guiducci8, Eleonora Celletti9, Addolorata Corrado10, Alessandro Giollo11, Simone Parisi12, Ivan Giovannini13, Elisa Gremese14, Garifallia Sakellariou15, Ombretta Viapiana16, Fabiola Atzeni17, Francesca Romana Spinelli18, Fabio Cacciapaglia1|19. | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy; 2Dipartimento di Scienze Mediche, Chirurgiche e Sperimentali, Università degli Studi di Sassari, Sassari, Italy; 3Rheumatology Unit, AOU Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 4Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Rheumatology Unit, Azienda Ospedaliera Universitaria Policlinico of Modena, Modena, Italy; 6Dpt of Rheumatology, G. Pini Institute, Milano, Italy; 7Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 8Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy; 9Rheumatology Unit, SS Annunziata Hospital, Chieti, Italy; 10Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 11Rheumatology Unit, Department of Medicine, University of Padova Hospital Trust, Padova, Italy; 12Rheumatology Department, A.O.U. Città della Salute e della Scienza, Torino, Italy; 13Rheumatology Department, Santa Maria della Misericordia Hospital, Udine, Italy; 14Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy; 15Department of Internal Medicine and Therapeutics, University of Pavia, Istituti Clinici Scientifici Maugeri, Pavia, Italy; 16Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy; 17Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy; 18Reumatology Unit, Department of Internal, Anesthesiological, and Cardiovascular Clinical Sciences, Sapienza University, Roma, Italy; 19Miulli General Hospital Acquaviva - Department of Medicine and Surgery, LUM F. De Gennaro University, Casamassima (BA), Acquaviva delle Fonti (BA), Italy.
92 -
The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases
2452PDF: 671SUPPLEMENTARY MATERIAL: 236 -
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
79 -
PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola1, Florenzo Iannone1, Francesco Paolo Cantatore2, Angelo Semeraro3, Leonardo Santo4, Roberto Gorla5, Alberto Cauli6, Roberto Felice Caporali7, Bruno Frediani8, Rosario Foti9, Fabrizio Conti10, Marco Sebastiani11, Maria Sole Chimenti12, Roberta Ramonda13, Fabiola Atzeni14, Maurizio Rossini15, Serena Bugatti16, Serena Guiducci17, Giovanni Lapadula1, Gianfranco Ferraccioli18, Francesca Romana Spinelli10, Elisa Gremese19. | 1Rheumatology Unit, DiMePReJ, University of Bari, Bari; 2Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; 3Rheumatology Unit, Martina Franca Hospital; 4Rheumatology Unit, ASL BT, P.O. Barletta; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; 6Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); 7Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; 8Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; 9Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; 10Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; 11Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; 12Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; 13Rheumatology Unit, DIMED, University of Padua, Padova; 14Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; 15Rheumatology Unit, Department of Medicine, University of Verona, Verona; 16Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; 17Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; 18Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; 19Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy
112 -
S13:5 | Association between vasoactive-vasodilating therapy and reduced detection of pulmonary arterial hypertension in systemic sclerosis: evidence from a European Scleroderma Trials and Research study Nicola Farina1, Silvia Bellando-Randone1, Sebastien Sanges2, Hilde Jenssen Bjørkekjær3, Lorenzo Tofani4, Marie-Elise Truchetet5, Vanessa Smith6, Andra Balanescu7, Christina Bergmann8, Yannick Allanore9, Philipp Klemm10, Simona Truglia11, Luca Idolazzi12, Christopher Denton13, Roberta Foti14, Anna Wojteczek15, Emmanuel Chatelus16, Madelon Vonk17, Serena Guiducci1, David Launay2, Eric Hachulla2, Jeska De Vries-Bouwstra18, Anna-Maria Hoffmann-Vold19, Oliver Distler20, Marco Matucci-Cerinic1, Cosimo Bruni1. | 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Az, Firenze, Italy; 2Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoi, Lille, France; 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway; 4Department of Statistics, Informatics and Applications, University of Florence, Firenze, Italy; 5Rheumatology department, CHU de Bordeaux, Bordeaux, France; 6University of Ghent, Department of Rheumatology, Gent, Belgium; 7Department of Rheumatology, St. Maria Hospital, Carol Davila, University of Medicine and Pharmacy Bucharest Romania; 8Department Internal Medicine 3, University Hospital Erlangen, Erlangen, Germany; 9Rheumatology Department, Université Paris Cité, Cochin Hospital, Paris, France; 10Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff Bad Nauheim Germany; 11Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy; 12Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy; 13Centre for Rheumatology, Royal Free London and University College London Medical School, London, United Kingdom; 14Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy; 15Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdansk, Univers Gdansk Poland; 16Department of Rheumatology, University Hospital Strasbourg Strasbourg France; 17Department of rheumatology, Radboud University Nijmegen Medical Center Nijmegen The Netherlands; 18Department of Rheumatology, Leiden University Medical Center Leiden The Netherlands; 19Department of Rheumatology, Oslo University Hospital, Oslo, Norway; 20Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
72 -
PO:07:102 | Predicting success with baricitinib in rheumatoid arthritis: efficacy across ages and serological profiles Daniele Lini1, Matteo Colina2, Romina Andracco3, Francesca Ometto4, Viviana Ravagnani5, Alberto Lo Gullo6, Simone Parisi7, Antonella Farina8, Patrizia Del Medico9, Marino Paroli10, Olga Addimanda1, Alessandra Bezzi11, Federica Lumetti12, Aldo Biagio Molica Colella13, Davide Murgia14, Maddalena Larosa15, Aurora Ianniello16, Elena Bravi17, Marta Priora18, Palma Scolieri19, Alessandro Volpe20. | 1Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- Azienda Ospedaliera Universitaria-IRCCS di Bologna, Bologna; 2Rheumatology Service. Department of Medicine and Oncology, Ospedale Santa Maria della Scaletta, Imola; 3Imperia Hospital, Internal Medicine Unit, Rheumatology outpatient clinic, Imperia; 4Azienda ULSS 6 Euganea, Rheumatology Outpatient Clinic, Padova; 5Santa Chiara Hospital APSS Trento, Rheumatology Unit, Trento; 6ARNAS Garibaldi di Catania, Rheumatology Unit, Catania; 7Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Rheumatology Department, Torino; 8Ospedale A. Murri di Fermo, Internal Medicine Unit, Rheumatology outpatient clinic, Fermo; 9Civitanova Marche Hospital, Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche; 10Sapienza University of Rome, Polo Pontino, Department of Clinical, Anesthesiological and Cardiovascular Sciences, Latina; 11ASL Romagna Rimini, Internal Medicine and Rheumatology Unit, Rimini; 12Azienda USL of Modena and University Hospital Policlinico di Modena, Rheumatology Unit, Modena; 13Rheumatology Unit, Azienda Ospedaliera Papardo, Messina; 14ASL VC Ospedale S. Andrea, Unit of Rheumatology, Vercelli; 15Azienda Sanitaria Locale 3 Genova, Division of Rheumatology - Medical Specialties Department, Genova; 16ASL Novara, Rheumatology Outpatient Unit, Novara; 17Ospedale G. Da Saliceto, Rheumatology Unit, Piacenza; 18ASL CN1, Rheumatology Day Hospital and outpatient clinic, Mondovì (CN); 19Nuovo Regina Margherita Hospital, Department of Medical Specialties, Roma; 20IRCCS Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Negrar, Italy.
73 -
PO:31:172 | Age and timing of onset of Raynaud's phenomenon and first non-Raynaud sign/symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the systemic sclerosis progression investigation registry of the Italian Society for Rheumatology Silvia Peretti1, Cosimo Bruni2, Silvia Laura Bosello3, Fabio Cacciapaglia4-5, Corrado Campochiaro6-7, Veronica Codullo8, Lorenzo Dagna6-7, Rossella De Angelis9, Giacomo De Luca6-7, Dilia Giuggioli10, Serena Guiducci1, Florenzo Iannone4, Francesca Ingegnoli11, Valeria Riccieri12, Marco Matucci Cerinic6-7, Clodoveo Ferri10-13, Silvia Bellando Randone1. | 1Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, AO, Firenze, Italy; 2Division of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 3Rheumatology Division, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli- IRCCS, Roma, Italy; 4Rheumatology Unit, Department of Precision and Regenerative Medicine-Ionian Area, University of Bari Aldo Moro, Bari, Italy; 5Reumatology Service, Internal Medicine Unit F.Miulli General Hospital, Acquaviva delle Fonti -Department of Medicine a, Bari, Italy; 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, Inflammation, Fibrosis and Ageing initiative INFL, Milano, Italy; 7Vita-Salute San Raffaele University, Milano, Italy; 8Department of Internal Medicine and Therapeutics, Università di Pavia, Italy; Division of Rheumatology, Fondazione IRCCS, Pavia, Italy; 9Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 10Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 11Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences and Community Health, Research Center for Adul, Milano, Italy; 12Department of Rheumatology, Sapienza University of Rome, Roma, Italy; 13Rheumatology Clinic Madonna dello Scoglio Crotonei, Crotone, Italy.
83 -
PO:35:219 | Real-world effectiveness of mepolizumab on gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a multicentre retrospective study Alessia Gatti1, Francesca Regola1, Giulia Fontana1, Mario Addrea Piga2, Gianluca Moroncini2, Palma Carlucci3, Angelo Vacca3, Paolo Delvino4, Enrico Heffler5, Emanuele Nappi5, Jakub Moll6, Laura Losappio6, Jan Schroeder6, Federica Davanzo7, Roberto Padoan7, Edoardo Conticini8, Paolo Cameli8, Greta Pacini9, Alvise Berti9, Lorenzo Vrola10, Paola Tomietto10, Luca Quartuccio11, Jan Willem Cohen Tervaert12, Sabrina Arnold13, Peter Lamprecht13, Florence Roufosse14, Ilaria Cavazzana1, Franco Franceschini1, Giacomo Emmi15, Paola Toniati1. | 1Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Italy, Brescia, Italy; 2Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, Ancona, Italy; 3Section of Internal Medicine 'Guido Baccelli', DiMePRe-J, University of Bari 'Aldo Moro', Bari, Italy, Bari, Italy; 4Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy Monza Italy; 5Department of Biomedical Sciences, Humanitas University and Personalized Medicine, Asthma and Allergy IRCCS Humanitas, Milano, Italy; 6Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Italy, Milano, Italy; 7Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy; 8University of Siena, Siena, Italy, Siena, Italy; 9Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy Trento Italy; 10UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, Trieste, Italy; 11Division of Rheumatology, Department of Medicine DMED, University of Udine, Udine, Italy, Udine, Italy; 12University of Alberta, Edmonton, Alberta, Canada and Maastricht University, Maastricht, The Netherlands Maastricht The Netherlands; 13Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany Lubeck Germany; 14Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Belgium Brussels Belgium; 15Clinical Medicine and Clinical Immunology and Rheumatology Unit Cattinara University Hospital and University of Trieste, Trieste, Italy.
100
